Esperion Therapeutics, Inc. announced the appointment of Stephen Rocamboli as a Class I director, with a term expiring at the 2023 annual meeting of stockholders. Mr. Rocamboli fills the newly created vacancy resulting from Dr. Mark McGovern's retirement from the Board. Mr. Rocamboli is currently Chief Executive Officer of Perla Therapeutics, Inc. Previously, he served as Chief Business Officer, General Counsel and Corporate Secretary of Candel Therapeutics, between April 2015 and May 2020 (CNDL).

Between 2010 and April 2015, Mr. Rocamboli served as general partner of Integrin Partners, LLC. Between 2010 and 2012, Mr. Rocamboli also served as partner of Beijing International Group. Between 2014 and 2015, he also served as Special Counsel to Wyrick Robbins Yates & Ponton, LLP, focusing on life sciences transactions.

Mr. Rocamboli held positions of increasing responsibility, with the last five years as Senior Managing Director and General Counsel of all business units. Mr. Rocamboli has served as a member of the board of directors of several public and private life sciences companies, including Foresight Biotherapeutics (sold to Shire Pharmaceuticals in 2015) and currently serves as a member of TFF Pharmaceuticals, Austin, TX (TFFP).